563 related articles for article (PubMed ID: 22869151)
21. The Role of Janus Kinase/STAT3 Pathway in Hematologic Malignancies With an Emphasis on Epigenetics.
Zeinalzadeh E; Valerievich Yumashev A; Rahman HS; Marofi F; Shomali N; Kafil HS; Solali S; Sajjadi-Dokht M; Vakili-Samiani S; Jarahian M; Hagh MF
Front Genet; 2021; 12():703883. PubMed ID: 34992627
[TBL] [Abstract][Full Text] [Related]
22. JAK kinase inhibitors for the treatment of acute lymphoblastic leukemia.
Degryse S; Cools J
J Hematol Oncol; 2015 Jul; 8():91. PubMed ID: 26208852
[TBL] [Abstract][Full Text] [Related]
23. Cytokine Signaling in Tumor Progression.
Lee M; Rhee I
Immune Netw; 2017 Aug; 17(4):214-227. PubMed ID: 28860951
[TBL] [Abstract][Full Text] [Related]
24. The Role and Therapeutic Targeting of JAK/STAT Signaling in Glioblastoma.
Ou A; Ott M; Fang D; Heimberger AB
Cancers (Basel); 2021 Jan; 13(3):. PubMed ID: 33498872
[TBL] [Abstract][Full Text] [Related]
25.
Downes CE; McClure BJ; McDougal DP; Heatley SL; Bruning JB; Thomas D; Yeung DT; White DL
Front Cell Dev Biol; 2022; 10():942053. PubMed ID: 35903543
[TBL] [Abstract][Full Text] [Related]
26. Acquired JAK2 mutations confer resistance to JAK inhibitors in cell models of acute lymphoblastic leukemia.
Downes CEJ; McClure BJ; Bruning JB; Page E; Breen J; Rehn J; Yeung DT; White DL
NPJ Precis Oncol; 2021 Aug; 5(1):75. PubMed ID: 34376782
[TBL] [Abstract][Full Text] [Related]
27. KLC1-ROS1 Fusion Exerts Oncogenic Properties of Glioma Cells via Specific Activation of JAK-STAT Pathway.
Fujii T; Nakano Y; Hagita D; Onishi N; Endo A; Nakagawa M; Yoshiura T; Otsuka Y; Takeuchi S; Suzuki M; Shimizu Y; Toyooka T; Matsushita Y; Hibiya Y; Tomura S; Kondo A; Wada K; Ichimura K; Tomiyama A
Cancers (Basel); 2023 Dec; 16(1):. PubMed ID: 38201436
[TBL] [Abstract][Full Text] [Related]
28. Predicting gene level sensitivity to JAK-STAT signaling perturbation using a mechanistic-to-machine learning framework.
Cheemalavagu N; Shoger KE; Cao YM; Michalides BA; Botta SA; Faeder JR; Gottschalk RA
bioRxiv; 2023 May; ():. PubMed ID: 37292918
[TBL] [Abstract][Full Text] [Related]
29. Fine-Tuning Cytokine Signals.
Lin JX; Leonard WJ
Annu Rev Immunol; 2019 Apr; 37():295-324. PubMed ID: 30649989
[TBL] [Abstract][Full Text] [Related]
30. JAK Kinases in Health and Disease: An Update.
Laurence A; Pesu M; Silvennoinen O; O'Shea J
Open Rheumatol J; 2012; 6():232-44. PubMed ID: 23028408
[TBL] [Abstract][Full Text] [Related]
31. Unraveling the Immunogenetics of STAT Proteins: Clinical Perspectives on Gain-of-Function and Loss-of-Function Variants.
Meesilpavikkai K; Hirankarn N; Dalm VASH; Hagen PMV; Dik WA; IJspeert H
Asian Pac J Allergy Immunol; 2024 Jun; 42(2):105-122. PubMed ID: 38710647
[TBL] [Abstract][Full Text] [Related]
32. Exploring the molecular mechanisms between lymphoma and myelofibrosis.
Wang JN; Li Y
Am J Transl Res; 2024; 16(3):730-737. PubMed ID: 38586105
[TBL] [Abstract][Full Text] [Related]
33. Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistance.
Quintás-Cardama A; Verstovsek S
Clin Cancer Res; 2013 Apr; 19(8):1933-40. PubMed ID: 23406773
[TBL] [Abstract][Full Text] [Related]
34. JAK kinase targeting in hematologic malignancies: a sinuous pathway from identification of genetic alterations towards clinical indications.
Springuel L; Renauld JC; Knoops L
Haematologica; 2015 Oct; 100(10):1240-53. PubMed ID: 26432382
[TBL] [Abstract][Full Text] [Related]
35. JAK/STAT pathway directed therapy of T-cell leukemia/lymphoma: Inspired by functional and structural genomics.
Waldmann TA
Mol Cell Endocrinol; 2017 Aug; 451():66-70. PubMed ID: 28214593
[TBL] [Abstract][Full Text] [Related]
36. Targeting the JAK-STAT pathway in lymphoma: a focus on pacritinib.
Derenzini E; Younes A
Expert Opin Investig Drugs; 2013 Jun; 22(6):775-85. PubMed ID: 23442043
[TBL] [Abstract][Full Text] [Related]
37. Mechanisms of Jak/STAT signaling in immunity and disease.
Villarino AV; Kanno Y; Ferdinand JR; O'Shea JJ
J Immunol; 2015 Jan; 194(1):21-7. PubMed ID: 25527793
[TBL] [Abstract][Full Text] [Related]
38. The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours.
Thomas SJ; Snowden JA; Zeidler MP; Danson SJ
Br J Cancer; 2015 Jul; 113(3):365-71. PubMed ID: 26151455
[TBL] [Abstract][Full Text] [Related]
39. The JAK-STAT pathway and hematopoietic stem cells from the JAK2 V617F perspective.
Staerk J; Constantinescu SN
JAKSTAT; 2012 Jul; 1(3):184-90. PubMed ID: 24058768
[TBL] [Abstract][Full Text] [Related]
40. JAK-STAT signaling in cancer: From cytokines to non-coding genome.
Pencik J; Pham HT; Schmoellerl J; Javaheri T; Schlederer M; Culig Z; Merkel O; Moriggl R; Grebien F; Kenner L
Cytokine; 2016 Nov; 87():26-36. PubMed ID: 27349799
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
